A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy is a research paper published in Statistical Methods in Medical Research (2022). On theSindex it has a DataRank of 0. It has been cited 12 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Louisiana Board of Regents
Grant: LEQSF(2020-21)-RD-A-04
National Cancer Institute
Grant: P30 CA082709;
National Cancer Institute
Grant: R21 CA264257
NCI NIH HHS
Grant: P30 CA082709
National Institutes of Health
Grant: 3P30CA082709-16S3
Indiana University Melvin and Bren Simon Cancer Center Support Grant
National Institutes of Health
Grant: 1R21CA264257-01
Curve-free phase I/II clinical trial designs for molecularly targeted agents and immunotherapy
Ralph W. and Grace M. Showalter Research Trust award
FWCI
0.60
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals